Literature DB >> 19738004

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.

Silvia Sookoian1, Gustavo O Castaño, Adriana L Burgueño, Tomas Fernández Gianotti, María Soledad Rosselli, Carlos Jose Pirola.   

Abstract

We explored the role of the adiponutrin (PNPLA3) nonsynonymous-rs738409 single nucleotide polymorphism (SNP) in genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) and whether this SNP contributes to the severity of histological disease. Two hundred sixty-six individuals were evaluated in a case-control association study, which included 172 patients with features of NAFLD and 94 control subjects. The rs738409 G allele was significantly associated with NAFLD (P < 0.001; OR 2.8 95%, CI 1.5-5.2), independent of age, sex, body mass index (BMI), and Homeostasis Model Assessment (HOMA) index. When we tested the hypothesis of a relation between the SNP and the histological spectrum of NAFLD, a significant association was observed [chi2 19.9, degree of freedom (df): 2, P < 5 x 10(-5), adjusted for HOMA and BMI]. The degree of liver steatosis, as evaluated by liver biopsy, was significantly associated with the rs738409 G allele. Patients with CC genotype showed a lower steatosis score (14.9% +/- 3.9) in comparison with the CG genotype (26.3% +/- 3.5) and GG genotype (33.3% +/- 4.0) (P < 0.005). The proportion of the total variation attributed to rs738409 genotypes was 5.3% (beta 0.23 +/- 0.07; P < 0.002). Our data suggest that the rs738409 G allele is associated not only with fat accumulation in the liver but also with liver injury, possibly triggered by lipotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738004      PMCID: PMC2739750          DOI: 10.1194/jlr.P900013-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  28 in total

Review 1.  Benefits of lifestyle modification in NAFLD.

Authors:  Stephen A Harrison; Christopher Paul Day
Journal:  Gut       Date:  2007-10-02       Impact factor: 23.059

2.  Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo Castaño; Carolina Gemma; Tomas-Fernández Gianotti; Carlos-Jose Pirola
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

3.  Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo Castaño; Tomas Fernández Gianotti; Carolina Gemma; María Soledad Rosselli; Carlos Jose Pirola
Journal:  Cytokine       Date:  2008-09-11       Impact factor: 3.861

Review 4.  Genes and nonalcoholic fatty liver disease.

Authors:  Nimantha Mark Wilfred de Alwis; Christopher Paul Day
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

5.  The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.

Authors:  Luca Miele; Gary Beale; Gillian Patman; Valerio Nobili; Julian Leathart; Antonio Grieco; Marilena Abate; Scott L Friedman; Goutham Narla; Elisabetta Bugianesi; Christopher P Day; Helen L Reeves
Journal:  Gastroenterology       Date:  2008-04-11       Impact factor: 22.682

Review 6.  Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.

Authors:  N J Barshop; C B Sirlin; J B Schwimmer; J E Lavine
Journal:  Aliment Pharmacol Ther       Date:  2008-04-04       Impact factor: 8.171

7.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Authors:  Anna Ludovica Fracanzani; Luca Valenti; Elisabetta Bugianesi; Marco Andreoletti; Agostino Colli; Ester Vanni; Cristina Bertelli; Erika Fatta; Daniela Bignamini; Giulio Marchesini; Silvia Fargion
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

8.  Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.

Authors:  Eleftheria Zeggini; Laura J Scott; Richa Saxena; Benjamin F Voight; Jonathan L Marchini; Tianle Hu; Paul I W de Bakker; Gonçalo R Abecasis; Peter Almgren; Gitte Andersen; Kristin Ardlie; Kristina Bengtsson Boström; Richard N Bergman; Lori L Bonnycastle; Knut Borch-Johnsen; Noël P Burtt; Hong Chen; Peter S Chines; Mark J Daly; Parimal Deodhar; Chia-Jen Ding; Alex S F Doney; William L Duren; Katherine S Elliott; Michael R Erdos; Timothy M Frayling; Rachel M Freathy; Lauren Gianniny; Harald Grallert; Niels Grarup; Christopher J Groves; Candace Guiducci; Torben Hansen; Christian Herder; Graham A Hitman; Thomas E Hughes; Bo Isomaa; Anne U Jackson; Torben Jørgensen; Augustine Kong; Kari Kubalanza; Finny G Kuruvilla; Johanna Kuusisto; Claudia Langenberg; Hana Lango; Torsten Lauritzen; Yun Li; Cecilia M Lindgren; Valeriya Lyssenko; Amanda F Marvelle; Christa Meisinger; Kristian Midthjell; Karen L Mohlke; Mario A Morken; Andrew D Morris; Narisu Narisu; Peter Nilsson; Katharine R Owen; Colin N A Palmer; Felicity Payne; John R B Perry; Elin Pettersen; Carl Platou; Inga Prokopenko; Lu Qi; Li Qin; Nigel W Rayner; Matthew Rees; Jeffrey J Roix; Anelli Sandbaek; Beverley Shields; Marketa Sjögren; Valgerdur Steinthorsdottir; Heather M Stringham; Amy J Swift; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Nicholas J Timpson; Tiinamaija Tuomi; Jaakko Tuomilehto; Mark Walker; Richard M Watanabe; Michael N Weedon; Cristen J Willer; Thomas Illig; Kristian Hveem; Frank B Hu; Markku Laakso; Kari Stefansson; Oluf Pedersen; Nicholas J Wareham; Inês Barroso; Andrew T Hattersley; Francis S Collins; Leif Groop; Mark I McCarthy; Michael Boehnke; David Altshuler
Journal:  Nat Genet       Date:  2008-03-30       Impact factor: 38.330

9.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

Authors:  Xin Yuan; Dawn Waterworth; John R B Perry; Noha Lim; Kijoung Song; John C Chambers; Weihua Zhang; Peter Vollenweider; Heide Stirnadel; Toby Johnson; Sven Bergmann; Noam D Beckmann; Yun Li; Luigi Ferrucci; David Melzer; Dena Hernandez; Andrew Singleton; James Scott; Paul Elliott; Gerard Waeber; Lon Cardon; Timothy M Frayling; Jaspal S Kooner; Vincent Mooser
Journal:  Am J Hum Genet       Date:  2008-10       Impact factor: 11.025

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  137 in total

1.  Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.

Authors:  Samer Gawrieh; Miranda C Marion; Richard Komorowski; James Wallace; Michael Charlton; Ahmed Kissebah; Carl D Langefeld; Michael Olivier
Journal:  Dig Dis Sci       Date:  2011-12-09       Impact factor: 3.199

2.  Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.

Authors:  Weiqin Chen; Benny Chang; Lan Li; Lawrence Chan
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 4.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

5.  Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study.

Authors:  Lynne E Wagenknecht; Nicholette D Palmer; Donald W Bowden; Jerome I Rotter; Jill M Norris; Julie Ziegler; Yii-Der I Chen; Steven Haffner; Ann Scherzinger; Carl D Langefeld
Journal:  Liver Int       Date:  2011-01-13       Impact factor: 5.828

6.  Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey D Browning; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

7.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

8.  Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.

Authors:  Sang Soo Lee; Young-Sang Byoun; Sook-Hyang Jeong; Byung Hyun Woo; Eun Sun Jang; Jin-Wook Kim; Hyun Young Kim
Journal:  Dig Dis Sci       Date:  2014-07-29       Impact factor: 3.199

9.  Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.

Authors:  Winston Dunn; Maura O'Neil; Jie Zhao; Chuang Hong Wu; Benjamin Roberts; Shweta Chakraborty; Craig Sherman; Brandy Weaver; Ryan Taylor; Jody Olson; Mojtaba Olyaee; Richard Gilroy; Timothy Schmitt; Yu-Jui Yvonne Wan; Steven A Weinman
Journal:  Hepatology       Date:  2013-12-23       Impact factor: 17.425

Review 10.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.